• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Exploring Pharmacogenetic Testing for Hypertension Management in China.

作者信息

Zhao Zhenping, Zhou Maigeng

机构信息

National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

出版信息

China CDC Wkly. 2023 Sep 1;5(35):785-787. doi: 10.46234/ccdcw2023.149.

DOI:10.46234/ccdcw2023.149
PMID:37745264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10515647/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e73b/10515647/f7b86c556455/ccdcw-5-35-785-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e73b/10515647/73aa8bfd72ec/ccdcw-5-35-785-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e73b/10515647/f7b86c556455/ccdcw-5-35-785-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e73b/10515647/73aa8bfd72ec/ccdcw-5-35-785-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e73b/10515647/f7b86c556455/ccdcw-5-35-785-2.jpg

相似文献

1
Exploring Pharmacogenetic Testing for Hypertension Management in China.探索中国高血压管理中的药物遗传学检测
China CDC Wkly. 2023 Sep 1;5(35):785-787. doi: 10.46234/ccdcw2023.149.
2
The Landscape of Clinical Implementation of Pharmacogenetic Testing in Central China: A Single-Center Study.中国中部地区药物遗传学检测的临床应用现状：一项单中心研究
Pharmgenomics Pers Med. 2021 Dec 14;14:1619-1628. doi: 10.2147/PGPM.S338198. eCollection 2021.
3
Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.中国雌激素受体阳性早期乳腺癌绝经后女性辅助内分泌治疗中 CYP2D6*10 基因检测指导的成本效果分析。
Clin Drug Investig. 2020 Jan;40(1):25-32. doi: 10.1007/s40261-019-00842-0.
4
Therapeutic Drug Monitoring and Pharmacogenetic Testing in Northern China.中国北方的治疗药物监测与药物遗传学检测
Front Pharmacol. 2021 Nov 2;12:754380. doi: 10.3389/fphar.2021.754380. eCollection 2021.
5
A systematic review of pharmacogenetic testing in primary care: Attitudes of patients, general practitioners, and pharmacists.一项针对初级保健中药物遗传学检测的系统评价：患者、全科医生和药剂师的态度。
Res Social Adm Pharm. 2022 Aug;18(8):3230-3238. doi: 10.1016/j.sapharm.2021.12.002. Epub 2021 Dec 15.
6
Pharmacogenetic testing, informed consent and the problem of secondary information.药物遗传学检测、知情同意与二次信息问题
Bioethics. 2004 Aug;18(4):344-60. doi: 10.1111/j.1467-8519.2004.00401.x.
7
Pharmacogenetic testing in pediatric neurology: a pragmatic study evaluating clinician and patient perceptions.儿科神经病学中的药物遗传学检测：一项评估临床医生和患者认知的实用研究。
Per Med. 2022 Sep;19(5):423-434. doi: 10.2217/pme-2021-0150. Epub 2022 Jul 13.
8
Modern molecular study of weight gain related to antidepressant treatment: clinical implications of the pharmacogenetic testing.与抗抑郁治疗相关的体重增加的现代分子研究：药物遗传学检测的临床意义
Rom J Morphol Embryol. 2018;59(1):165-173.
9
Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation.药物遗传学检测预防药物不良反应：系统评价经济评估以及对临床实践和实施的质量评估。
BMC Health Serv Res. 2021 Oct 2;21(1):1042. doi: 10.1186/s12913-021-07025-8.
10
Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.促进和阻碍在城市内人群中采用药物遗传学检测的因素。
Pharmacotherapy. 2018 Feb;38(2):205-216. doi: 10.1002/phar.2077. Epub 2018 Jan 21.

引用本文的文献

1
The Implementation and Outcomes of Personalized Antihypertensive Therapy Based on Pharmacogenetic Testing: A Retrospective Study Examining Blood Pressure Control and Medication Tolerability.基于药物遗传学检测的个性化抗高血压治疗的实施与结果：一项关于血压控制和药物耐受性的回顾性研究
Cureus. 2024 Nov 23;16(11):e74288. doi: 10.7759/cureus.74288. eCollection 2024 Nov.

本文引用的文献

1
Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial.四种降压药物血压反应的异质性：一项随机临床试验。
JAMA. 2023 Apr 11;329(14):1160-1169. doi: 10.1001/jama.2023.3322.
2
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.一个 12 基因药物遗传学检测面板以预防药物不良反应：一项开放标签、多中心、对照、集群随机交叉实施研究。
Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4.
3
Prevalence, awareness, treatment, and control of hypertension in China, 2004-18: findings from six rounds of a national survey.
2004-2018 年中国高血压的流行、知晓、治疗和控制情况：来自六轮全国调查的结果。
BMJ. 2023 Jan 11;380:e071952. doi: 10.1136/bmj-2022-071952.
4
Primary care institutional characteristics associated with hypertension awareness, treatment, and control in the China PEACE-Million Persons Project and primary health-care survey: a cross-sectional study.在中国高血压调查和基层医疗服务调查（China PEACE-Million Persons Project and primary health-care survey）中，与高血压知晓率、治疗率和控制率相关的基层医疗服务机构特征：一项横断面研究。
Lancet Glob Health. 2023 Jan;11(1):e83-e94. doi: 10.1016/S2214-109X(22)00428-4.
5
Demand for Direct-to-Consumer Genetic Testing Services in China and Its Implications for Precision Public Health - China, 2021.中国直接面向消费者的基因检测服务需求及其对精准公共卫生的影响 - 中国，2021年
China CDC Wkly. 2022 Aug 12;4(32):715-719. doi: 10.46234/ccdcw2022.149.
6
Investigating hypertension in younger patients.调查年轻患者的高血压情况。
BMJ. 2022 Mar 24;376:e067924. doi: 10.1136/bmj-2021-067924.
7
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.全球高血压患病率趋势及 1990 至 2019 年治疗和控制进展情况：1040 万参与者、1201 项人群代表性研究的汇总分析
Lancet. 2021 Sep 11;398(10304):957-980. doi: 10.1016/S0140-6736(21)01330-1. Epub 2021 Aug 24.
8
Genomics of hypertension: the road to precision medicine.高血压的基因组学：通向精准医学之路。
Nat Rev Cardiol. 2021 Apr;18(4):235-250. doi: 10.1038/s41569-020-00466-4. Epub 2020 Nov 20.
9
Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.204 个国家和地区 1990-2019 年 87 种风险因素的全球负担：2019 年全球疾病负担研究的系统分析。
Lancet. 2020 Oct 17;396(10258):1223-1249. doi: 10.1016/S0140-6736(20)30752-2.
10
Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good.将药物基因组学转化为临床决策：不要让完美成为优秀的敌人。
Hum Genomics. 2019 Aug 27;13(1):39. doi: 10.1186/s40246-019-0229-z.